32 results about "Lung deposition" patented technology

The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies and/or increase lung deposition.

Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible.

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies and/or increase lung deposition.

The invention discloses an oral lung inhalation aerosol powder, which can improve the lung deposition rate of active ingredients of the aerosol powder, avoid the deposition of carrier micropowder in the lung, and increase the stability of the composition. The oral lung inhalation aerosol powder consists of the active ingredients and the carrier micropowder. The oral lung inhalation aerosol powder is characterized in that: the mean grain size of the micropowder of the active ingredients is between 0.5 and 10 mu m, and the mean grain size of the carrier micropowder is between 20 and 45 mu m.

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies and/or increased lung deposition.

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies and/or increase lung deposition.

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies, and/or increased lung deposition.

The invention discloses an asarone dry powder inhalant and a method for preparing the same. The method for preparing the asarone dry powder inhalant includes steps: mixing asarone with auxiliary materials, and allowing the mixture to contact with high-speed air flow with crushing pressure being 0.4-0.7Mpa to be crushed to obtain micro powder, wherein the mass percentage content of the asarone ranges from 50% to 100%, and the mass percentage content of the auxiliary materials ranges from 0% to 50%; and mixing the micro powder with a medically acceptable carrier to obtain the asarone dry powder inhalant. The asarone dry powder inhalant is a novel agent and simple in preparation process, asarone medicine can be micronized, and lung deposition rate is increased. Further, the asarone dry powder inhalant has the advantages of quickness in effect, convenience in use and carrying, high stability and the like and is clinically widely applicable to treatment of asthma, chronic obstructive pulmonary disease and the like.

The invention relates to a powder aerosol capable of resisting to idiopathic pulmonary fibrosis and a preparation method thereof, and belongs to the field of medicinal preparations. The powder aerosol includes, by weight in parts, 80-95 parts of active pharmaceutical ingredients, 2.5-20 parts of an endogenous pulmonary surfactant, and 0-10 parts of calcium salt. The particle volume geometric diameter of the powder aerosol is 0.5-6 [mu]m. The powder aerosol has a less and narrow geometric diameter distribution, so that the powder aerosol can directly reach the lesion. A lung deposition rate FPF value is greater than 50%. An FPF value (3.4) is greater than 30%, which refers to a deep lung deposition pattern. The powder aerosol can be delivered to the depth of the lung to achieve a clinical effect of anti-pulmonary fibrosis; the dosage of active ingredients of drugs can be reduced; and therefore, adverse reactions caused by the increasing of the dosage of the active ingredients can be reduced to a greater extent.

The invention relates to the field of medical products, in particular to a method for preparing a betamethasone dipropionate atomization inhalant. The method comprises the following steps: dispersing betamethasone dipropionate into water to obtain suspension, homogenizing, sterilizing, and thus obtaining the betamethasone dipropionate atomization inhalant, wherein the homogenizing pressure is 200 to 2,000 bar. The preparation method is green and environment-friendly, simplifies the operation steps, can realize continuous operation, and is short in acting time, sterile, pollution-free and suitable for industrialized production. The prepared betamethasone dipropionate atomization inhalant has the advantages of high dispersion stability, high lung deposition rate, low medicament consumption, high bioavailability and low toxic or side effect.

The invention discloses a preparation method for drug-carrier mode composite micro-powder. The composite micro-powder structure takes a fumed silica aggregate as a carrier; the fumed silica aggregate is located in the center of the composite micro-powder particles; drug particles are adsorbed on the surface of the carrier; the geometric particle size of the fumed silica aggregate is 1-30 microns; the geometric particle size of the drug particles is 10-1,000 nm; and the aerodynamic particle size of the composite micro-powder particles is less than 10 microns. The preparation method taking pentoxyverine citrate as a representative drug comprises the following steps: preparing a pentoxyverine citrate suspension with a high-pressure homogenization, reactive precipitation or anti-solvent precipitation method, wherein the geometric particle size of suspension particles is 10-1,000 nm; adding the fumed silica aggregate into the suspension, and mixing uniformly, wherein the mass percentage of the fumed silica aggregate to the pentoxyverine citrate is 15-60% to 40-85%; and spray-drying a mixed suspension to obtain the composite micro-powder. The preparation method is simple in process, low in cost and short in cycle. Compared with carrier-free mode micro-powder, the composite micro-powder has more excellent aerodynamic performance, lung deposition performance, flowability and dispersity.

The invention provides an inhalation aerosol containing an anticholinergic drug, a preparation process and an application method of the inhalation aerosol. The inhalation aerosol consists of an activeingredient ipratropium bromide, or a monohydrate or a pharmaceutically acceptable salt thereof, a hydrofluoroalkane propellant, a latent solvent absolute ethyl alcohol and a pH regulator. The inhalation aerosol provided by the invention can achieve an effective lung deposition rate meeting requirements, and meanwhile, the drug stability is remarkably improved; meanwhile, the inhalation aerosol can be used in combined utilization with a mist storage device, the medication compliance of old people and children is improved, the curative effect of medicine used by patients is improved, and side effects are reduced.

The invention discloses a preparing method of medicine-additive mode composite micro powder. The composite micro powder is structurally characterized in that medicine particles with the geometric particle size of 1-10 microns are located in the centers, additive modified gas-phase white carbon black with the geometric particle size of 10-65 nm are adsorbed to the surfaces of the medicine particles, and the aerodynamics particle size of particles of the composite micro powder is smaller than 10 microns. The preparing method with pentoxyverine as representative medicine includes the following steps that a modifying agent for the modified gas-phase white carbon black is prepared from one or more of hexamethyldisilazane, cyclo-silazane and octyltriethoxysilane, and the geometric particle size of the modified gas-phase white carbon black is 10-65 nm; pentoxyverine turbid liquid is prepared, wherein the geometric particle size of turbid particles is 1-10 microns; the modified gas-phase white carbon black is added into the turbid liquid, wherein the mass percent of the additive to the medicine is 10-70%:30-90%; the mixed turbid liquid is subjected to spray drying, and the composite micro powder is obtained. The preparing method is simple in technology, low in cost and short in period. Compared with carrier-free-mode micro powder, the composite micro powder has the more excellent aerodynamics performance, the more excellent lung deposition performance, the more excellent fluidity and the more excellent dispersion degree.